Artificial Internalizing Receptor Affords Fast, Potent, Specific Drug Delivery to the Chemically Engineered Cells
Source abstract
Abstract
Abstract Receptors are lipid bilayer‐resident molecules that perform a myriad of functions in a cell, from recognition to signaling and solute internalization, and are typically based on proteins. Herein, artificial receptors are engineered based on small organic molecules, toward chemical, non‐genetic engineering of cells. Specifically, artificial internalizing receptors are designed for selective targeting and cell‐specific drug delivery. The artificial receptors are shown to afford nanomolar potency of action for the cognate antibody‐drug conjugates. In the chemically engineered cells, the conjugate activity is at the same time more potent and significantly faster than that observed with the use of the pristine drug. In a mixed cell population, an antibody‐drug conjugate targeted to the artificial receptor can selectively eliminate the chemical receptor‐engineered cells. Taken together, these results illustrate that artificial receptors based on small organic molecules are simple by structure but can mediate one of the foundational cellular functions, namely endocytosis, with excellence. Most importantly, these receptors are truly bio‐orthogonal and thus afford a dedicated route of communication with the chemically engineered cells.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: CAR-T cell therapy research · RNA Interference and Gene Delivery · Viral Infectious Diseases and Gene Expression in Insects
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
iNano Interdisciplinary Nanoscience Center Aarhus University Aarhus 8000 Denmark
Department of Chemistry Aarhus University Aarhus 8000 Denmark
Funding
Novo Nordisk Fonden · Danmarks Frie Forskningsfond
References (32)
Show source-provided references
1. 10.1038/s41580-018-0068-010.1038/s41580-018-0068-0 ↗
2. 10.1038/ncomms886610.1038/ncomms8866 ↗
3. 10.1038/s41589-021-00790-x10.1038/s41589-021-00790-x ↗
4. 10.1038/s41589-021-00798-310.1038/s41589-021-00798-3 ↗
5. Berg J. M. · 2023
6. 10.1093/hesc/9780198866664.001.000110.1093/hesc/9780198866664.001.0001 ↗
7. 10.1038/s41573-022-00476-610.1038/s41573-022-00476-6 ↗
8. 10.1038/s41571-023-00754-110.1038/s41571-023-00754-1 ↗
9. 10.1021/jacsau.2c0034410.1021/jacsau.2c00344 ↗
10. 10.1039/D2CS00142J10.1039/D2CS00142J ↗
11. 10.1016/j.addr.2021.01.01010.1016/j.addr.2021.01.010 ↗
12. 10.1002/advs.20230404010.1002/advs.202304040 ↗
13. 10.1021/cb300119g10.1021/cb300119g ↗
14. 10.1016/j.chembiol.2018.05.00910.1016/j.chembiol.2018.05.009 ↗
15. 10.1038/s41571-021-00470-810.1038/s41571-021-00470-8 ↗
16. 10.1021/bc990059z10.1021/bc990059z ↗
17. 10.1021/ja062377w10.1021/ja062377w ↗
18. 10.1021/ja017087o10.1021/ja017087o ↗
19. 10.1021/ja025873310.1021/ja0258733 ↗
20. 10.1021/bc025601p10.1021/bc025601p ↗
21. 10.1021/ja067674f10.1021/ja067674f ↗
22. 10.1002/advs.20200139510.1002/advs.202001395 ↗
23. Kymriah® product information https://www.ema.europa.eu/en/documents/product‐information/kymriah‐epar‐product‐information_en.pdf(accessed: February2024).
24. 10.1007/s10928-016-9495-810.1007/s10928-016-9495-8 ↗
25. 10.1021/bc050291710.1021/bc0502917 ↗
26. 10.1038/nbt.228910.1038/nbt.2289 ↗
27. 10.1002/cbic.20200026110.1002/cbic.202000261 ↗
28. 10.1038/s41571-019-0297-y10.1038/s41571-019-0297-y ↗
29. 10.1016/S1470-2045(18)30864-710.1016/S1470-2045(18)30864-7 ↗
30. 10.1056/NEJMoa170986610.1056/NEJMoa1709866 ↗
31. 10.1056/NEJMoa170744710.1056/NEJMoa1707447 ↗
32. 10.1056/NEJMoa180498010.1056/NEJMoa1804980 ↗